Перспективы применения дорназы альфа в детской респираторной медицине
https://doi.org/10.18093/0869-0189-2011-0-5-97-102
Аннотация
Перспективы применения дорназы альфа в детской респираторной медицине.
Об авторе
И. К. ВолковРоссия
д. м. н., проф. кафедры детских болезней
119992, Москва, ул. Большая Пироговская, 19. Тел.: (499) 248-42-66.
Список литературы
1. Lucas A.M., Douglas L.C. Principles underlying ciliary activity in the respiratory tract. II. A comparison of nasal clearance in man, monkey and other mam-mals. Arch. Otolaryngol. 1934; 20: 518–541.
2. Sleigh M. Mucus propulsion. In: Crystal R.G., West J.B. et al., eds. The lung: scientific fundations. New York: Raven Press Ltd.; 1991; vol. 1: 189–197.
3. Nadel J.A. New approaches to regulation of fluid secretion in airways. Chest 1981; 80 (Suppl): 849–851.
4. Picot R., Das I., Reid L. Pus desoxyribonucleic acid and sputum viscosity. Thorax 1978; 33: 235–242.
5. Stutts M.J., Canessa C.M., Olsen J.C. et al. CFTR as a cAMP-dependent regulator of sodium channels. Science 1995; 269: 847–850.
6. Lieberman J. Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis. J.A.M.A. 1968; 205: 312–313.
7. Shak S., Capon D.J., Hellmiss R. et al. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc. Nat. Acad. Sci. USA 1990; 87: 9188–9192.
8. Pinder J.C., Gratzer W.B. Investigation of the actin-deoxyribonuclease I interaction using a pyreneconjugated actin derivative. J. Biochem. (Tokyo) 1982; 21: 4886–4890.
9. Anselmo M.A.,Lands L.C. Cystic fibrosis. In: Pediatric respiratory medicine. St. Louis; 2008. Mosby; 845–907.
10. Matthews L.W., Spector S., Lemm J., Potter J.L. The overall chemical composition of pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy. Am. Rev. Respir. Dis. 1963; 88: 199–204.
11. Rozov T., de Oliveira V.Z., Santana M.A. et al. Dornase alfa improves the health-related quality of life among Brazilian patients with cystic fibrosis – a one-year prospective study. Pediatr. Pulmonol. 2010; 45 (9): 874–882.
12. Капpанов Н.И., Гембицкая Т.Е., Симонова О.И. и др. Опыт длительного применения нового муколитического препарата "Пульмозим" у больных муковисцидозом. Тер. арх. 2001; 1: 55–58.
13. Волков И.К. Возможности использования дорназы альфа (пульмозим) в детской пульмонологии. Пульмонология 2004; 4: 113–117.
14. Quan J.M., Tiddens H.A.W.M., Sy J.P. et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis and mild lung function abnormalities. J. Pediatr. 2001: 139: 813–820.
15. Liou T.G., Adler F.R., Fitz Simmons S.C. et al. Predictive 5-year survivorship model of cystic fibrosis. Am. J. Immunol. 2001; 153: 345–352.
16. Shah P.L., Conway S., Scott S.F. et al. A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4 year period. Respiration 2001; 68: 160–164.
17. Hodson M.E., McKenzie S., Harms H.K. et al. Dornase alfa in the treatment of cystic fibrosis in Europe: a report from the epidemiologic registry of cystic fibrosis. Pediatr. Pulmonol. 2003; 36 (5): 427–432.
18. Hodson M.E., Shah P.L. Dnase trials in cystic fibrosis. Eur. Respir. J. 1995; 8: 1786–1791.
19. Fuchs H.J., Borowitz D.S., Christiansen D.H. et al. Effect of aerosolized recombinant human Dnase on exacerbations of respiratory symptoms and on pulmonary functions in patients whit cystic fibrosis: the Pulmozyme study group. N. Engl. J. Med. 1994; 331: 637–642.
20. Mainz J.G., Schiller I., Ritschel C. et al. Sinonasal inhalation of dornase alfa in CF: A double-blind placebo-controlled crossover pilot trial. Auris Nasus Larynx 2011; 38 (2): 220–227.
21. Dentice R., Elkins M. Timing of dornase alfa inhalation for cystic fibrosis. Cochrane Database Syst. Rev. 2011; 5: CD007923.
22. Jones A.P., Wallis C.E. Dornase alpha for cystic fibrosis. Cochrane Database Syst. Rev. 2010; 3:CD001127.
23. Kristensen K. Recombinant human DNase in conditions other than cystic fibrosis. Ugeskr. Laeg. 2010; 172 (8): 616–619.
24. Волков И.К., Давыдова И.В., Куличихин В.Г. и др. Эффективность дорназы альфа (пульмозим) у детей с хроническими заболеваниями легких. Пульмонология 2003; 3: 79–82.
25. Puchelle E., Zahm J.M., de Bentzmann S. et al. Effects of rhDNase on purulent airway secretions in chronic bronchitis. Eur. Respir. J. 1996; 9 (4): 765–769.
26. Berge M., Brinkhorst G., Kroon A.A., Jongste J.C. DNase treatment in primary ciliary dyskinesia-assessment by nocturnal pulse oximetry. Pediatr. Pulmonol. 1999; 27: 59–61.
27. Merkus P.J., de Hoog M., van Gent R., de Jongste J.C. DNase treatment for atelectasis in infants with severe respiratory syncytial virus bronchiolitis. Eur. Respir. J. 2001; 18 (4): 734–737.
28. Nasr S.Z., Strouse P.J., Soskolne E. et al. Efficacy of recombinant human deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis. Chest 2001; 120: 203–208.
29. Kupeli S., Teksam O, Dogru D., Yurdakok M. Use of recombinant human DNase in a premature infant with recurrent atelectasis. Pediatr. Intern. 2003; 45: 584–586.
30. El Hassan N.O., Chess P.R., Huysman M. et al. Rescue use of DNase in critical lung atelectasis and mucus retention in premature neonates. Pediatrics 2001; 108: 468–471.
31. Hendriks T., de Hoog M., Lequin M.H. et al. DNase and atelectasis in non-cystic fibrosis pediatric patients. Crit. Care 2005; 9 (4): R35–R356.
32. Durward A., Forte V., Shemie S.D. Resolution of mucus plugging and atelectasis after intratracheal rhDNase therapy in a mechanically ventilated child with refractory status asthmaticus. Crit. Care Med. 2000; 28 (2): 560–562.
33. Manna S.S., Shaw J., Tibby S.M. A Durward treatment of plastic bronchitis in acute chest syndrome of sickle cell disease with intratracheal rhDNase. Arch. Dis. Child. 2003; 88: 626–627.
34. Scherer T., Geller D.E., Owyang L. et al. A technical feasibility study of dornase alfa delivery with eFlow® vibrating membrane nebulizers: aerosol characteristics and physicochemical stability. J. Pharm. Sci. 2011; 100 (1): 98–109.
35. Bush A. Bronchoscopy in paediatric intensive care. Paediatr. Respir. Rev. 2003: 4 (1): 67–73.
36. Slattery D.M., Waltz D.A., Denham B. et al. Bronchoscopically administered recombinant human DNase for lobar atelectasis in cystic fibrosis. Pediatr. Pulmonol. 2001; 31 (5): 383–388.
37. Simpson G., Roomes D., Reeves B. Successful treatment of empyema thoracis with human recombinant deoxyribonuclease. Thorax 2003; 58: 363–366.
38. Conway S.P. Evidence-based medicine in cystic fibrosis: how should practice change? Pediatr. Pulmonol. 2002; 34: 242–247.
39. Капранов Н.И., Воронкова А.Ю., Шабалова Л.А. и др. Клиническое значение рекомбинантной человеческой ДНКазы (Пульмозим) в комплексной терапии больных муковисцидозом. Рос. педиатр. журн. 2001; 3: 26–31.
40. McKenzie S.G., Chowdhury S., Strandvik B., Hodson M.E. Dornase alfa is well tolerated: data from the epidemiologic registry of cystic fibrosis. Pediatr. Pulmonol. 2007; 42 (10): 928–937.
Рецензия
Для цитирования:
Волков И.К. Перспективы применения дорназы альфа в детской респираторной медицине. Пульмонология. 2011;(5):97-102. https://doi.org/10.18093/0869-0189-2011-0-5-97-102
For citation:
Volkov I.K. Perspectives for treatment with dornase-alfa in paediatric respiratory medicine. PULMONOLOGIYA. 2011;(5):97-102. (In Russ.) https://doi.org/10.18093/0869-0189-2011-0-5-97-102